ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure
Justine E Marum, David T Yeung, Leanne Purins, John Reynolds, Wendy T Parker, Doris Stangl, Paul PS Wang, David J Price, Jonathan Tuke, Andreas W Schreiber, Hamish S Scott, Timothy P Hughes, Susan Branford
Blood Advances | AMER SOC HEMATOLOGY | Published : 2017
Awarded by National Health and Medical Research Council of Australia
This work was supported by the National Health and Medical Research Council of Australia grants APP1059165 (T.P.H. and S.B.), APP1104425 (S.B.), APP1059165 and APP1023059 (H.S.S.), the Royal Adelaide Hospital Research Foundation, a scholarship from the Leukaemia Foundation of Australia and the AR Clarkson Foundation (D.T.Y.), and a postdoctoral fellowship from the Leukaemia Foundation of Australia/Cure Cancer Australia (W.T.P.). The Australian Cancer Research Foundation (ACRF) Cancer Genomics Facility was established with funding from Therapeutic Innovation Australia and the ACRF.